Ontology highlight
ABSTRACT:
SUBMITTER:
PROVIDER: S-EPMC3585949 | biostudies-literature | 2011
REPOSITORIES: biostudies-literature
Drugs in R&D 20110101 2
RVX 208 (RVX-208; RVX000222) is a first-in-class novel small molecule in development by Resverlogix Corporation for acute coronary syndromes, atherosclerosis and Alzheimer disease. It increases the levels of apolipoprotein A1 and high-density lipoprotein cholesterol, thereby potentially reducing the risk for cardiovascular disease. This review discusses the key development milestones and therapeutic trials of this drug. This summary has been extracted from Wolters Kluwer's R&D Insight drug pipel ...[more]